New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
NYS Entity Status
NYS Filing Date
JULY 02, 2014
NYS DOS ID#
MICHAEL DAVID SAIDIAN
124-15 METROPOLITAN AVE 2NS FL
KEW GARDENS, NEW YORK, 11415
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2014 - BEN DAVID DEVELOPMENT LLC
Around the Web
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
- Insane amount of fentanyl seized in record-breaking bust
By Rebecca Rosenberg - Monday Sep 18, 2017
Law enforcement agents seized a record haul of street-grade fentanyl from a Queens building — ?marking ?the largest ?such bust ?in New York City history, officials announced Monday. NYPD and DEA agents recovered 64 kilograms of the lethal drug from a residential address in Kew Gardens on Aug?. 1 as part of a broader pair...
- Ben Stiller’s ‘Brad’s Status’ Tops Indie Box Office With $100K
By Jeremy Fuster, provided by
- Sunday Sep 17, 2017
Off the heels of its premiere at the Toronto International Film Festival, Amazon/Annapurna’s “Brad’s Status” made just over $100,000 from its limited opening in four theaters to lead the indie box office weekend.Written and directed by Mike White, the film stars Ben Stiller as a father who takes his son (Austin Abrams) on an east coast college tour. Along the way, he meets an old friend whose success makes him question his life choices. White produced the film with Brad Pitt, Dede Gardener, Sidney Kimmel and David Bernad. The film has received strong reviews, earning an 83 percent score on Rotten Tomatoes.
- How Does the Hamptons Garden Grow? With a Lot of Paid Help
By STACEY STOWE - Wednesday Sep 6, 2017
On the East End of Long Island, the professionally planted and tended vegetable garden requires a different kind of green.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]